Navigation Links
Experimental Vitiligo Treatment Shows Promise in Mice
Date:2/27/2013

WEDNESDAY, Feb. 27 (HealthDay News) -- A genetically modified protein could provide the first effective treatment for the skin condition vitiligo, a new study in mice suggests.

People with vitiligo have white patches on the face, hands and other parts of the body. Vitiligo is an autoimmune disorder in which the immune system becomes overactive and kills the pigment cells that give skin its color.

Researchers at the Loyola University Chicago Stritch School of Medicine developed a genetically modified protein that reversed vitiligo in mice and had similar effects on human skin tissue samples. Findings from animal studies do not always hold up in human trials, however.

A protein called HSP70i plays a major role in the autoimmune response that causes vitiligo. The researchers genetically modified an amino acid in the protein in order to create a mutant version of HSP70i. This version replaces normal HSP70i and reverses the autoimmune response that causes vitiligo, the study authors explained in a Loyola news release.

When the mutant HSP70i was given to mice with vitiligo, their salt-and-pepper fur turned black, giving them a normal appearance. The mutant protein had a similar effect on human skin samples, according to the study, published in the current issue of the journal Science Translational Medicine.

Researcher I. Caroline Le Poole, a professor in Loyola's Oncology Institute, and colleagues are seeking approval and funding to conduct a clinical trial of the modified protein in humans.

About 1 million Americans have vitiligo, which affects about one in 200 people worldwide. There are no long-term effective treatments for the condition. Current options include steroid creams, light therapy and skin grafts, but none of them can prevent vitiligo from progressing.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about vitiligo.

-- Robert Preidt

SOURCE: Loyola University Health System, news release, Feb. 27, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Harmful effects of bisphenol A proved experimentally
2. Experimental agent briefly eases depression rapidly in test
3. NIH-funded trial launched to assess experimental TB drug
4. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
5. Experimental Antidepressant Appears Quick-Acting, Safe
6. More than a third of high-risk leukemia patients respond to an experimental new drug
7. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
8. Experimental Insomnia Drug Shows Promise
9. Experimental Dengue Vaccine Shows Some Success
10. Standard chemotherapy provides higher survival rate than experimental in lung cancer patients
11. Cancer turns off important immune cells, complicating experimental vaccine therapies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Vitiligo Treatment Shows Promise in Mice
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: